Amity Institute of Biotechnology (AIBNK), Amity University, Rajarhat, Newtown Action Area 2, Kolkata, 700135, West Bengal, India.
Metabolomics. 2024 Mar 8;20(2):37. doi: 10.1007/s11306-024-02100-7.
Lipids play key roles in numerous biological processes, including energy storage, cell membrane structure, signaling, immune responses, and homeostasis, making lipidomics a vital branch of metabolomics that analyzes and characterizes a wide range of lipid classes. Addressing the complex etiology, age-related risk, progression, inflammation, and research overlap in conditions like Alzheimer's Disease, Parkinson's Disease, Cardiovascular Diseases, and Cancer poses significant challenges in the quest for effective therapeutic targets, improved diagnostic markers, and advanced treatments. Mass spectrometry is an indispensable tool in clinical lipidomics, delivering quantitative and structural lipid data, and its integration with technologies like Liquid Chromatography (LC), Magnetic Resonance Imaging (MRI), and few emerging Matrix-Assisted Laser Desorption Ionization- Imaging Mass Spectrometry (MALDI-IMS) along with its incorporation into Tissue Microarray (TMA) represents current advances. These innovations enhance lipidomics assessment, bolster accuracy, and offer insights into lipid subcellular localization, dynamics, and functional roles in disease contexts.
The review article summarizes recent advancements in lipidomic methodologies from 2019 to 2023 for diagnosing major neurodegenerative diseases, Alzheimer's and Parkinson's, serious non-communicable cardiovascular diseases and cancer, emphasizing the role of lipid level variations, and highlighting the potential of lipidomics data integration with genomics and proteomics to improve disease understanding and innovative prognostic, diagnostic and therapeutic strategies.
Clinical lipidomic studies are a promising approach to track and analyze lipid profiles, revealing their crucial roles in various diseases. This lipid-focused research provides insights into disease mechanisms, biomarker identification, and potential therapeutic targets, advancing our understanding and management of conditions such as Alzheimer's Disease, Parkinson's Disease, Cardiovascular Diseases, and specific cancers.
脂质在许多生物过程中发挥着关键作用,包括能量储存、细胞膜结构、信号转导、免疫反应和内稳态,因此脂质组学是代谢组学的一个重要分支,分析和描述广泛的脂质类别。在寻求有效的治疗靶点、改进诊断标志物和先进治疗方法时,阿尔茨海默病、帕金森病、心血管疾病和癌症等疾病的复杂病因、与年龄相关的风险、进展、炎症以及研究重叠等问题都带来了重大挑战。质谱分析是临床脂质组学中不可或缺的工具,提供定量和结构脂质数据,它与液相色谱(LC)、磁共振成像(MRI)和一些新兴的基质辅助激光解吸电离成像质谱(MALDI-IMS)等技术的整合,以及与组织微阵列(TMA)的结合,代表了当前的进展。这些创新增强了脂质组学评估的准确性,并深入了解了脂质在亚细胞定位、疾病背景下的动态变化和功能作用。
综述总结了 2019 年至 2023 年期间用于诊断主要神经退行性疾病(阿尔茨海默病和帕金森病)、严重非传染性心血管疾病和癌症的脂质组学方法的最新进展,强调了脂质水平变化的作用,并突出了脂质组学数据与基因组学和蛋白质组学的整合在改善疾病理解和创新预后、诊断和治疗策略方面的潜力。
临床脂质组学研究是一种有前途的方法,可以跟踪和分析脂质谱,揭示它们在各种疾病中的关键作用。这种以脂质为重点的研究提供了对疾病机制、生物标志物识别和潜在治疗靶点的深入了解,提高了我们对阿尔茨海默病、帕金森病、心血管疾病和特定癌症等疾病的理解和管理水平。